ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report)'s share price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $44.98 and traded as high as $48.40. ProShares Ultra Nasdaq Biotechnology shares last traded at $48.34, with a volume of 4,898 shares changing hands.
ProShares Ultra Nasdaq Biotechnology Stock Performance
The business's 50 day simple moving average is $44.98 and its 200-day simple moving average is $48.74. The stock has a market capitalization of $53.17 million, a price-to-earnings ratio of 20.68 and a beta of 1.63.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Tuesday, July 1st. Shareholders of record on Wednesday, June 25th were given a dividend of $0.1706 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 1.41%. This is an increase from ProShares Ultra Nasdaq Biotechnology's previous quarterly dividend of $0.13. The ex-dividend date was Wednesday, June 25th.
Institutional Trading of ProShares Ultra Nasdaq Biotechnology
A number of hedge funds and other institutional investors have recently made changes to their positions in BIB. Crowley Wealth Management Inc. bought a new stake in shares of ProShares Ultra Nasdaq Biotechnology during the 4th quarter worth about $51,000. Tower Research Capital LLC TRC raised its holdings in shares of ProShares Ultra Nasdaq Biotechnology by 31.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,326 shares of the exchange traded fund's stock worth $270,000 after purchasing an additional 1,266 shares in the last quarter. IMC Chicago LLC bought a new stake in shares of ProShares Ultra Nasdaq Biotechnology in the 1st quarter worth approximately $1,080,000. Finally, PNC Financial Services Group Inc. bought a new stake in shares of ProShares Ultra Nasdaq Biotechnology in the 1st quarter worth approximately $48,000.
About ProShares Ultra Nasdaq Biotechnology
(
Get Free Report)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.
While ProShares Ultra Nasdaq Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
